Stockreport

Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults [Globe and Mail, The (Toronto, Canada)]

Ascendis Pharma A/S - American Depositary Shares  (ASND) 
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ascendispharma.com
PDF Yorvipath ® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipa [Read more]